The likelihood of metabolic interactions of lamivudine with other medicinal products is low due to the small extent of hepatic metabolism (5-10%) and low plasma protein binding.
Kuna maksametabolismi osa on väike (5... 10%) ja seonduvus plasmavalkudega samuti, ei ole tõenäoline, et esineksid koostoimed teiste ravimitega.